Discure Technologies Announces $16 Million in Financing Led by BOLD Capital Partners, Supernova Invest and Sanara Capital
Funds will advance the clinical testing of Discure’s breakthrough device for degenerative disc disease
PETACH-TIKVA, Israel, Sept. 10, 2024 /PRNewswire/ — Discure Technologies Ltd., developer of the Discure System, a bioelectronic implantable device for the treatment of degenerative disc disease (DDD), announced today that the Company has secured $11 million in an oversubscribed Series A financing round, following a SAFE (Simple Agreement for Future Equity) raise of $5 million, bringing the total equity financing raised to $16 million. The Series A round was led by BOLD Capital Partners, Supernova Invest and Sanara Capital, with participation from multiple US hospital networks, leading orthopedic surgeons, veteran medtech industry investors, and existing investors, underscoring their collective confidence in Discure’s vision, strategy, innovative solution and the significant market opportunity.
